Related Experiment Videos
S-adenosylmethionine and affective disorder.
M W Carney1, B K Toone, E H Reynolds
1Department of Psychiatry, Northwick Park Hospital, Harrow, England.
The American Journal of Medicine
|November 20, 1987
Summary
Studies suggest S-adenosylmethionine (SAMe) may offer antidepressant effects, particularly for endogenous depression. Further research is needed to fully understand its neuropharmacology and mechanisms.
Area of Science:
- Neuroscience
- Psychiatry
- Biochemistry
Background:
- S-adenosylmethionine (SAMe) is a naturally occurring compound involved in crucial biochemical pathways.
- SAMe plays a role in transmethylation, folate metabolism, and monoamine metabolism.
- It is also implicated in membrane function and neurotransmission.
Purpose of the Study:
- To review existing evidence on the antidepressant effects of SAMe.
- To explore the potential mechanisms of SAMe's action on mood disorders.
- To identify areas for future research regarding SAMe's neuropharmacology.
Main Methods:
- Review of open and double-blind studies on SAMe and depression.
- Analysis of SAMe's biochemical and physiological roles.
- Exploration of neuropharmacological pathways involved in mood regulation.
Main Results:
- Multiple studies indicate SAMe may possess antidepressant properties.
- Evidence suggests a selective benefit for endogenous depression over neurotic depression.
- SAMe is confirmed to cross the blood-brain barrier and is involved in key metabolic pathways.
Conclusions:
- SAMe shows promise as a potential treatment for certain types of depression.
- Further investigation into its neuropharmacological effects, particularly on the dopaminergic system, is warranted.
- SAMe is a non-toxic physiological substance with a favorable safety profile, excluding potential mania induction in susceptible individuals.